博文
诺和诺德糖尿病疗法达3期主要终点
||
https://mp.weixin.qq.com/s/xhNSrQZseJhr02ypir479w
诺和诺德（Novo Nordisk）在今年上半年投资者会议上宣布其糖尿病在研疗法IcoSema在关键3期试验COMBINE 1当中取得积极结果，该公司预定在今年下半年向中国、美国、欧盟的监管单位递交该疗法用于治疗2型糖尿病（T2D）患者的上市申请。
http://www.pubmedplus.cn/P/SearchQuickResult?wd=6cd79d6c-3bcb-45e0-8dd8-2c3471e5850b
1. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
From the Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City (M.N.K.); Novo Nordisk, Søborg (S.Z.A., S.R., G.K.H., M.L.L., D.V.M., M.B.T.), and the Department of Cardiology, Herlev-Gentofte Hospital, University of Copenhagen, Herlev (M. Schou) - both in Denmark; the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.); Baylor Scott and White Research Institute, Dallas (J.B.); the Department of Medicine, University of Mississippi, Jackson (J.B.); Diabetes Research Centre, University of Leicester, and National Institute for Health and Care Research Leicester Biomedical Research Centre (M.D.), Leicester, the Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester (F.Z.A.), and the School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (M.C.P.) - all in the United Kingdom; the Department of Cardiovascular Medicine and Section on Geriatrics and Gerontology, Wake Forest School of Medicine, Winston-Salem, NC (D.W.K.); the Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago (S.J.S.); the Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Unity Health Toronto, University of Toronto, Toronto (S.V.), and University of Alberta, Edmonton (J.E.) - both in Canada; the College of Health and Medicine, the Australian National University, Canberra, ACT, Australia (W.A.); Max Super Specialty Hospital, New Delhi, India (V.C.); the Section of Cardiology, Department of Medicine, Sahlgrenska University Hospital-Ostra, Gothenburg, Sweden (M.F.); the Department of General Internal Medicine 3, Kawasaki Medical School, Okayama, Japan (H.I.); the Department of Noninvasive Cardiology, Medical University of Lodz, Lodz, Poland (M.L.); the Institute for Clinical and Experimental Medicine, Prague, Czech Republic (V.M.); the Heart and Vascular Center, Semmelweis University, Budapest, Hungary (B.M.); Hospital Clínico Universitario de Valencia, INCLIVA, Universidad de Valencia, and CIBER (Centro de Investigación Biomédica en Red) Cardiovascular, Valencia, Spain (J.N.); Instituto de Cardiologia J.F. Cabral, Corrientes, Argentina (E.P.); ASST (Azienda Sociosanitaria Territoriale) Papa Giovanni XXIII, Bergamo, Italy (M. Senni); John Hopkins Hospital, Baltimore (K.S.); the Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (P.V.M.); Medical University of Graz, Graz, Austria (D.L.); and Cardiology and Angiology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany (D.W.).
N Engl J Med (P 1533-4406 E 0028-4793) H指数：933 2023 年 389 卷 12 期 1069-1084 页
PMID：37622681 相似文献
2. Predictors of weight loss outcomes in obesity care: results of the national ACTION study.
Nikhil V Dhurandhar,Theodore Kyle,Boris Stevenin,Kenneth Tomaszewski,
Texas Tech University, Lubbock, TX, USA. Nikhil.Dhurandhar@ttu.edu.
Nikhil.Dhurandhar@ttu.edu
BMC Public Health (P 1471-2458 E 1471-2458) H指数：117 2019 年 19 卷 1 期 1422 页
PMID：31666040 相似文献
https://blog.sciencenet.cn/blog-280034-1446403.html
上一篇：ACC/AHA更新心衰质量评估指标
下一篇：脑小血管病患者需要吃阿司匹林、他汀吗？
